Dawnrays Pharmaceutical Sees Core Earnings Edge Up as One-Off Gains Drop Off

An update from Dawnrays Pharmaceutical Holdings Ltd. ( (HK:2348) ) is now available.

Dawnrays Pharmaceutical reported 2025 revenue of RMB1.23 billion, up 16.1% year on year, with gross profit rising 6% to RMB612.2 million but gross margin narrowing to 49.7%. Profit attributable to shareholders dropped 62.1% to RMB214.0 million, as the prior year was boosted by substantial non-recurring gains.

Excluding 2024’s one-off income, underlying profit to the parent grew 6.1%, highlighting more modest core earnings momentum than the headline decline suggests. The board maintained the interim and proposed final dividends but removed last year’s special payout, cutting the full-year dividend by one-third and signaling a more cautious capital return stance amid weaker reported profitability.

The most recent analyst rating on (HK:2348) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Dawnrays Pharmaceutical Holdings Ltd. stock, see the HK:2348 Stock Forecast page.

More about Dawnrays Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical (Holdings) Limited is a Cayman Islands–incorporated drug maker listed in Hong Kong, operating in the pharmaceutical industry. The group focuses on manufacturing and selling pharmaceutical products in China, deriving revenue from a portfolio that includes finished drugs and related healthcare products.

Average Trading Volume: 192,033

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.67B

For detailed information about 2348 stock, go to TipRanks’ Stock Analysis page.